The global urinalysis market is expected to grow at a compound annual growth rate of 5.72% over the forecast period to reach a market size of US$3.875 billion in 2026 from US$2.625 billion in 2019.
A urinalysis is a urine test that is used to diagnose and treat a variety of conditions, including urinary tract infections (UTI), kidney disease, and diabetes. During a urinalysis, the appearance, concentration, and content of urine are all evaluated. Abnormal urine findings may indicate a condition or illness. In September 2021, according to Eurek Aert, the Translational Genomics Research Institute (TGen), a City of Hope affiliate, had discovered a method to pinpoint early-stage cancer by utilising Urinalysis to analyse small strands of cell-free DNA in urine. Various non-invasive urine automated analyzers have been developed to provide rapid and accurate test results.
The increased prevalence of UTIs, diabetes, and kidney and liver disorders, as well as the growing geriatric population and the resulting increase in age-related diseases, are driving market expansion. In hospitals and other critical care units and medical-surgical units, the prevalence of conditions such as UTI, renal disease, and diabetes is likely to be greater. According to the National Centre of Biotechnology Information, one-third of women will have experienced a UTI by the age of 24, and half by the age of 32. According to the International Diabetes Federation, about 463 million individuals, between the age of 20-79 years, had diabetes in 2019, and this number is expected to grow to 700 million by 2045. Furthermore, according to the National Kidney Foundation, chronic kidney disease (CKD) affects 10% of the world's population, with millions dying each year.
However, the market expansion is likely to be hampered in the coming years by a strict regulatory framework and an unfavourable reimbursement condition.
Due to an ageing population and a high prevalence of CKD, the North American market is projected to have a significant market position. Kidney failure, high blood pressure, and diabetes are all linked to chronic kidney disease. According to the National Kidney Foundation, each year more people die due to CKD than breast cancer and prostate cancer. In the United States, kidney disease is a major cause of death. It now affects around 37 million individuals in the US. It is more common in the ageing population, affecting around 15% of the adult population. Kidney disease affects around one in every three individuals with diabetes and one in every five adults with high blood pressure. Hence, there is a growing demand for accurate detection and treatment of CKD, and these factors are likely to drive up demand for urinalysis.
Geriatric population and age-related diseases are on the rise:
The growing geriatric population in developed and developing countries will boost the urinalysis market growth. According to the World Health Organization, the number of adults aged 60 and more will surpass children under the age of five by 2020. The prevalence of age-related diseases such as diabetes, kidney and liver disease is projected to rise dramatically as the geriatric population grows. According to the International Diabetes Organization, one in every five persons over the age of 65 has diabetes. Prescriptions for tests such as creatinine, albumin, glucose, ketones, and bilirubin, among others, are on the rise as a result of the increased diagnosis and treatment of such disorders, which is benefiting urinalysis, which is used to perform these tests.
The availability of refurbished instruments, which provide the same functionality as new equipment at a cheaper cost, poses a barrier to market growth. A number of end customers, primarily small and medium-sized laboratories, choose cost-effective reconditioned equipment. Particularly in developing nations, where markets are price-sensitive, inexpensive instruments with equivalent functions are preferred. This is likely to limit the revenue of companies who sell branded analyzers, thus limiting the market growth.
The COVID-19 outbreak had a detrimental impact on the total revenue of many market players. Lockdowns imposed due to the pandemic prompted patients to postpone or delay their health checkups, thus reducing the number of tests conducted and reagent sales. However, as governments increasingly loosen restrictions, there is a rise in testing numbers. Furthermore, COVID-19 is more likely to target individuals with kidney disease, kidney transplant patients, and those at risk for kidney disease, according to the National Kidney Foundation.
|Market size value in 2019||US$2.625 billion|
|Market size value in 2026||US$3.875 billion|
|Growth Rate||CAGR of 5.72% from 2019 to 2026|
|Forecast Unit (Value)||USD Billion|
|Segments covered||Product Type, Test Type, Application, End-User, And Geography|
|Regions covered||North America, South America, Europe, Middle East and Africa, Asia Pacific|
|Companies covered||ARKRAY, Inc., 77 Elektronika Kft., Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Abbott Laboratories, Sysmex Corporation, Neomedica d.o.o., Mindray Medical International Limited, Analis sa/nv|
|Customization scope||Free report customization with purchase|
Frequently Asked Questions (FAQs)
Q1. What will be the urinalysis market size by 2026?
A1. The global urinalysis market is expected to reach a total market size of US$3.875 billion in 2026.
Q2. What are the growth prospects for the urinalysis market?
A2. The urinalysis market is expected to grow at a CAGR of 5.72% over the forecast period.
Q3. What is the size of the global urinalysis market?
A3. Urinalysis Market was valued at US$2.625 billion in 2019.
Q4. What factors are anticipated to drive urinalysis market growth?
A4. The increased prevalence of UTIs, diabetes, and kidney and liver disorders, as well as the growing geriatric population and the resulting increase in age-related diseases, are driving urinalysis market expansion.
Q5. Which region holds the largest market share in the urinalysis market?
A5. The North American region is projected to have a significant share of the urinalysis market due to an ageing population and a high prevalence of CKD.
77 Elektronika Kft.
Siemens Healthineers AG
F. Hoffmann-La Roche Ltd.
Beckman Coulter, Inc.
Mindray Medical International Limited
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.